If you have seen a headline saying PCOS has been renamed and wondered whether it affects you, the short answer is: the name changed, and nothing about your diagnosis did.
The longer answer is more interesting than most renamings, because the reason given is that the old name described a thing that is not there.
The new name
Polyendocrine metabolic ovarian syndrome — PMOS.
It was announced on 12 May 2026, at the European Congress of Endocrinology in Prague, and published in The Lancet by a group writing as the Global Name Change Consortium. The lead author is Helena Teede, who also led the 2023 international guideline that every medical statement on this site is sourced to.
That continuity is worth noting. This is not a competing faction proposing a rival term; it is the same people who wrote the current diagnostic and treatment guidance, concluding that the name on it was wrong.
Why the old name was judged wrong
The core objection is factual and it is one this site has written about before: the “cysts” are not cysts.
What an ultrasound shows in this condition is a larger-than-usual number of ordinary small follicles — what the scan is actually counting — each containing an immature egg. Every ovary has them. They are not pathological growths, and calling them cysts describes a different thing entirely.
Two harms follow from that, and both are specific rather than theoretical:
People are told their ovarian cysts are explained. If you believe your condition produces cysts, an actual ovarian cyst looks like something already accounted for, and the risk is that something else goes uninvestigated.
People without the ultrasound finding get dismissed. A name that points at the ovaries invites a clinician to look there first, which leaves someone with irregular cycles, hyperandrogenism and a normal scan arguing for a diagnosis they already meet the criteria for — because two of three is the rule, and the scan is only one of them.
The broader argument is about proportion. The condition’s metabolic features — the ones the guideline asks everyone to be screened for, at any weight — are not in the name at all, while a non-specific imaging finding is the whole of it.
What actually changed, and what did not
| The name | Changed — polycystic ovary syndrome becomes polyendocrine metabolic ovarian syndrome |
| The acronym | Changed — PCOS becomes PMOS |
| The diagnostic criteria | Unchanged — still two of three, as the 2023 guideline sets out |
| Treatment recommendations | Unchanged — the guideline stands as published |
| Your diagnosis | Unchanged — you have the same condition you had last week |
| Your records | Will say PCOS, for years |
The announcement was about nomenclature. It did not revise the criteria, and it did not reclassify anyone.
The process, which is the unusual part
Most renamings are a committee and a journal. This one ran for more than a decade, starting with a meeting in Sicily in October 2015 that participants describe as having ended agreeing on very little except that the name was bad.
What followed was three rounds of global surveys — the last reaching close to fifteen thousand stakeholders in 2025 — then workshops, then multiple rounds of voting. In the final vote, 87 of 90 voters backed the winning name immediately.
The survey asked people to rank what a new name should achieve, and the order is the part worth knowing: avoiding stigma first, ease of communication second, scientific accuracy third. PMOS beat two other finalists, endocrine metabolic ovulatory syndrome and ovulatory metabolic endocrine syndrome.
Teede has said publicly that the most accurate name might have been slightly different from the one chosen — an unusually candid thing to say about your own result, and an accurate description of what happens when you rank stigma above precision on purpose.
Not everyone agrees
Two things are worth reporting rather than smoothing over.
The objection from some patient organisations is not that the new name is worse, but that changing the acronym imposes a real cost — books, charities, domains, services all built on four letters — without settling the questions people most wanted settled. Angela Grassi of the PCOS Nutrition Center and Sasha Ottey of PCOS Challenge both said so publicly.
The retained word is “ovarian.” Early research into a possible expression of the condition in men makes that a contested choice, and it was reportedly among the most debated points. Keeping it means the name still locates the condition in an organ not everyone affected has.
Against that, a quarter or fewer of survey respondents wanted to prioritise keeping the old acronym, and more than half rejected keeping it unchanged, on the grounds that a change that changed none of the letters would not be a change.
What this means for you, practically
Nothing medical. Not a new test, not a new appointment, not a reason to revisit anything.
Expect both names for a while. The stated expectation is roughly three years of promotion and dissemination, and records systems move more slowly than journals. Your notes, your referrals and your test results will say PCOS, and that is correct — it is what the condition was called when they were written.
It is useful to know the new one. If a clinician uses PMOS, or a letter arrives with it, it is the same condition. And knowing why the name changed is genuinely useful at an appointment, because the reasoning — the cysts are not cysts, the scan is one criterion of three — is the same reasoning that gets someone with a normal ultrasound taken seriously.
What this site will call it
PCOS, mostly, for now — and this is a deliberate choice rather than inertia.
Almost everyone looking for this information is still searching for the old name, and a page that answers only to the new one is a page that does not reach the person who needs it. That will change, and when it does, so will the wording here. Both terms will appear in the meantime, which is the honest reflection of where the transition actually is.
The app is called PCOS Juno. It will keep that name while that is the name people use for what they have.